The abstract is read at the publisher; the summary is JClub's.
Adjunct sitagliptin added to ATG-based prophylaxis significantly reduced grade II–III acute graft-versus-host disease by day +100 (14.7% vs 31.6%; sHR 0.41; P=.005) in alternative-donor transplants.
- Why it matters: Acute GVHD remains a major complication after haploidentical or unrelated donor hematopoietic stem-cell transplantation, and improved prophylaxis is needed to lower early severe disease.
- What they did: In a prospective multicenter open-label randomized phase III trial, 190 patients age 18–60 received myeloablative haploidentical or unrelated donor transplantation and were assigned 1:1 to ATG-based prophylaxis with or without sitagliptin 600 mg every 12 hours from days -1 to +14.
- The result: Sitagliptin also showed lower grade II–III and intestinal aGVHD and higher day +180 GVHD-free, relapse-free survival (86.3% vs 72.6%; HR 0.44; P=.016), while chronic GVHD, survival outcomes, and infection reactivation were not significantly different.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.